Feasibility of electronic brachytherapy in cervix cancer–A dosimetric comparison of different brachytherapy techniques

• Published in: Brachytherapy Vol. 21; no. 4; pp. 389 - 396
• Main Authors: Lozares-Cordero, Sergio, Gonzalez-Perez, Victor, Pellejero-Pellejero, Santiago, Rodriguez-Ruiz, Lucia, Guinot-Rodriguez, Jose Luis, Villafranca-Iturre, Elena, Méndez-Villamón, Agustina, Gandía-Martínez, Almudena, Fuentemilla-Urío, Naiara, Ruggeri, Ricardo
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-07-2022
• Subjects: Cervical cancer; Electronic brachytherapy; Embrace study; MRI guided radiotherapy; Electronic brachytherapy; Embrace study; Cervical cancer; MRI guided radiotherapy
• ISSN: 1538-4721; 1873-1449
• DOI: 10.1016/j.brachy.2022.01.006

This study analyzes cases in which electronic brachytherapy (eBT) led to acceptable treatment plans in cervical cancer. Findings were compared with dosimetry values obtained in 192Ir-based treatments according to the high-risk clinical target volume (HR-CTV) and the disease stage.
We retrospectively analyzed 48 patients with cervical cancer from two centers. The patients were treated with 192Ir based on MRI. It was possible to use interstitial needles via an Utrecht-type applicator. Dosimetry was simulated using eBT and the parameters D90 and D98 (HR-CTV) and D2cc, D1cc, and D0.1cc (bladder, rectum, and sigmoid colon) were evaluated. The Mann-Whitney U test was used for comparison. The overall cohort of patients was analyzed, as were the sub-cohorts based on stage (FIGO stages I+IIA, IIB and III–IV). Finally, the dosimetry of the eBT plans was evaluated, and the plans obtained were classified as “good”, “acceptable”, or “poor”.
Statistically significant differences were found between the eBT and 192Ir plans for D98 (HR-CTV), D1cc and D0.1cc (bladder), and D1cc and D0.1cc (sigmoid colon). A total of 31 cases (64.6%) were considered good, seven (14.6%) were considered acceptable, and 10 (20.8%) were considered poor. For volumes <30 cc, all the plans were good or acceptable; for volumes >30 cc, 54.3% were good, and 71.4% were good or acceptable. By stage, eBT plans for patients with stage IB–IIA disease were good in 100%, whereas those for patients with stage IIB were good in 70.6% and III–IV disease were good in 50%.
eBT provides appropriate dosimetry for treatment of cervical cancer in selected cases.